Clayton Partners LLC Sells 15,205 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Clayton Partners LLC sold 15,205 shares of Cellebrite DI Ltd., reducing its holdings by 12.1% during the first quarter, bringing its total shares to 110,879.
• Several hedge funds, including Voss Capital LP and Invesco Ltd., increased their positions in Cellebrite DI, indicating a wider interest in the company among institutional investors.
• Cellebrite DI reported a 18.4% increase in revenue year-over-year and beat earnings estimates with an EPS of $0.12 for the most recent quarter.

Clayton Partners LLC lowered its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 12.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 110,879 shares of the company's stock after selling 15,205 shares during the period. Cellebrite DI accounts for 1.9% of Clayton Partners LLC's portfolio, making the stock its 27th largest holding. Clayton Partners LLC's holdings in Cellebrite DI were worth $2,154,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its holdings in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in Cellebrite DI during the fourth quarter valued at approximately $1,015,000. Public Employees Retirement Association of Colorado acquired a new position in Cellebrite DI during the fourth quarter valued at approximately $465,000. Northern Trust Corp grew its holdings in Cellebrite DI by 113.6% during the fourth quarter. Northern Trust Corp now owns 211,994 shares of the company's stock valued at $4,670,000 after purchasing an additional 112,731 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $16,205,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 1.8%

CLBT stock traded up $0.29 during midday trading on Wednesday, hitting $16.65. The stock had a trading volume of 653,575 shares, compared to its average volume of 1,670,133. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of -21.92, a P/E/G ratio of 2.98 and a beta of 1.28. Cellebrite DI Ltd. has a 52 week low of $13.10 and a 52 week high of $26.30. The stock has a 50-day simple moving average of $15.01 and a 200 day simple moving average of $17.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the company posted $0.10 earnings per share. The business's revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several research reports. Wall Street Zen raised Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Needham & Company LLC reduced their price objective on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Lake Street Capital reduced their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.